Day One Biopharmaceuticals, Inc. financial data

Symbol
DAWN on Nasdaq
Industry
Pharmaceutical Preparations
Location
2000 Sierra Point Parkway, Suite 501, Brisbane, CA
State of incorporation
DE
Fiscal year end
December 31
Former names
Day One Biopharmaceuticals Holding Co LLC (to 5/26/2021)
Latest financial report
10-K/A - Q4 2024 - Mar 6, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 783 %
Debt-to-equity 15 % +115%
Return On Equity -23 % +55.5%
Return On Assets -20 % +58.6%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 101M shares +16%
Common Stock, Shares, Outstanding 101M shares +15.9%
Entity Public Float 972M USD +28.1%
Common Stock, Value, Issued 10K USD +11.1%
Weighted Average Number of Shares Outstanding, Basic 93.2M shares +16.9%
Weighted Average Number of Shares Outstanding, Diluted 93.2M shares +16.9%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 93.8M USD
Research and Development Expense 228M USD +74.5%
General and Administrative Expense 115M USD +52.8%
Operating Income (Loss) -217M USD -5.44%
Nonoperating Income (Expense) 6.52M USD +23.3%
Income Tax Expense (Benefit) -882K USD
Net Income (Loss) Attributable to Parent -95.5M USD +49.5%
Earnings Per Share, Basic -1.02 USD/shares +57%
Earnings Per Share, Diluted -1.02 USD/shares +57%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 125M USD -45.9%
Inventory, Net 3.32M USD
Other Assets, Current 322M USD +20.6%
Assets, Current 562M USD +49.8%
Property, Plant and Equipment, Net 2.29M USD +999%
Operating Lease, Right-of-Use Asset 2.42M USD +588%
Assets 583M USD +55%
Accounts Payable, Current 3.26M USD +26.6%
Liabilities, Current 73.5M USD +149%
Operating Lease, Liability, Noncurrent 2.59M USD
Other Liabilities, Noncurrent 761K USD
Liabilities 80M USD +171%
Accumulated Other Comprehensive Income (Loss), Net of Tax 84K USD +833%
Retained Earnings (Accumulated Deficit) -554M USD -20.8%
Stockholders' Equity Attributable to Parent 503M USD +45.1%
Liabilities and Equity 583M USD +55%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -49.7M USD -91.4%
Net Cash Provided by (Used in) Financing Activities 1.18M USD
Net Cash Provided by (Used in) Investing Activities 89.3M USD
Common Stock, Shares Authorized 500M shares 0%
Common Stock, Shares, Issued 101M shares +15.9%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 125M USD -45.9%
Deferred Tax Assets, Valuation Allowance 155M USD +64.7%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.21 pure
Deferred Tax Assets, Gross 157M USD +66.4%
Operating Lease, Liability 2.6M USD +538%
Payments to Acquire Property, Plant, and Equipment 0 USD -100%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -95.4M USD +49.5%
Lessee, Operating Lease, Liability, to be Paid 4.38M USD +933%
Property, Plant and Equipment, Gross 243K USD +106%
Operating Lease, Liability, Current 10K USD -97.5%
Lessee, Operating Lease, Liability, to be Paid, Year Two 432K USD
Lessee, Operating Lease, Liability, to be Paid, Year One 350K USD -17.5%
Operating Lease, Weighted Average Discount Rate, Percent 0.13 pure +44.4%
Deferred Income Tax Expense (Benefit) 900K USD
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 1.78M USD +11000%
Lessee, Operating Lease, Liability, to be Paid, Year Three 445K USD
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 6.37M USD +142%
Lessee, Operating Lease, Liability, to be Paid, Year Four 459K USD
Additional Paid in Capital 1.06B USD +31.3%
Depreciation, Depletion and Amortization 23K USD +283%
Share-based Payment Arrangement, Expense 48.3M USD +22.7%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%